Document Type : Original Article


1 Jarallah German Specialized Clinic

2 Department of Cellular and Molecular, Faculty of Life Sciences, North Tehran Branch, Islamic Azad University, Faculty of Biological Sciences, Tehran, Iran


The increasing literature exploring the role of circulating miR-210 has clarified its potential as a promising biomarker for early detection, diagnosis and prognosis. Measuring circulating miR-210 levels could be a non-invasive method for early cancer detection. Even if, to date, most studies appear to be preliminary it seems that miR-210 will be a good target for drug development. In this study, we had detected the difference of serum miR-210 expression between health and breast cancer patients. total of 15 breast cancer patients were selected for the breast cancer (BC) group and 15 healthy people. The results showed The expression level of miR-210 in the serum of breast cancer patients was significantly higher compared with that in healthy individuals. Patients with breast cancer present increased levels of circulating miR-210; thus, circulating miR-210 may be a potential biomarker of tumor presence and therapeutic response in breast cancer


1. Wang X, Zhu J (2018). Mir-1307 regulates cisplatin resistance by targetingMdm4 in breast cancer expressing wild type P53. Thorac Cancer, 9: 676-683.
Perou CM, Sørlie T, Eisen MB et al (2000). Molecular portraits of human breast tu-mours. Nature, 406: 747-752.
3. Zindy F, Kawauchi D, Lee Y et al (2014). Role of the miR-17∼92 cluster family in cerebellar and medulloblastoma devel-opment. Biol Open, 3: 597-605.
4. Murphy BL, Obad S, Bihannic L et al (2013). Silencing of the miR-17~92 clus-ter family inhibits medulloblastoma pro-gression. Cancer Res, 73: 7068-7078.
5. Qiu X, Dou Y (2017). miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. Biomed Pharmacother, 88: 430-435.
6. Iorio MV, Ferracin M, Liu CG et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65: 7065-7070.
7. Potter JW, Jones KB, Barrott JJ (2018). Sar-coma-The standard-bearer in cancer dis-covery. Crit Rev Oncol Hematol, 126: 1-5.
8. Mirzaei HR, Sahebkar A, Mohammadi M et al (2016). Circulating microRNAs in Hepatocellular Carcinoma:Potential Diag-nostic and Prognostic Biomarkers. Curr Pharm Des, 22: 5257-5269.
9. Sekar D, Krishnan R, Thirugnanasam-bantham K, Rajasekaran B, Islam VI, Sekar P (2016). Significance of microRNA 21 in gastric cancer. Clin Res Hepatol Gas-troenterol, 40: 538-545.
10. Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K (2016). Genetic and epigenetic hetero-geneity of epithelial ovarian cancer and the clinical implications for moleculartar-geted therapy. J Cell Mol Med, 20: 581-593.
11. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007). miR-21-mediated tumor growth. Oncogene, 26: 2799-2803.
12. Lee JA, Lee HY, Lee ES, Kim I, Bae JW (2011). Prognostic implications of mi-croRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer, 14: 269–275.
13. Guo W, Lian S, Zhen L et al (2018). The fa-vored mechanism for coping with acute cold stress:upregulation of miR-210 in rats. Cell Physiol Biochem, 46: 2090-2102.
14. Chan SY, Loscalzo J (2010). MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle, 9: 1072-1083.
15. Król M, Motyl T (2014). Exploiting cancer genomics in pet animals to gain ad-vantage for personalized medicine deci-sions. J Appl Genet, 55: 337-341.